<div id="readability-page-1"><p>In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Hold rating on Moderna, with a price target of <span id="expert-recommendation-target">$49.00</span>.</p><h3>TipRanks' Prime Week Sale - 70% Off</h3><ul><li> Unlock powerful  investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.</li><li> Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.</li></ul> <p>Salveen Richter has given his Hold rating due to a combination of factors that balance Moderna’s long-term opportunities with near-term execution risk. While the company’s Science Day showcased a broadening oncology and autoimmune pipeline, many of the highlighted programs, including the multi-antigen T-cell engager and cancer antigen therapies, remain in early stages with key readouts pushed into 2027 and beyond.</p> <p>Richter sees the Merck-partnered individualized neoantigen therapy, intismeran, as the primary near-term catalyst, with upcoming Phase 3 adjuvant melanoma data likely to drive the stock’s direction. At the same time, the intact $49 price target reflects both confidence in the mRNA platform’s scalability and caution around the competitive landscape, long development timelines, and the need for disciplined spending and partnerships to fund expansion into oncology and autoimmune indications.</p> <p>According to TipRanks, Richter is a 5-star analyst with an average return of <span>11.2%</span> and a 47.53% success rate. Richter covers the Healthcare sector, focusing on stocks such as Moderna, Regeneron, and Agios Pharma.</p> <p>In another report released today, Citi also maintained a Hold rating on the stock with a $41.00 price target.</p></div>

MRNA

MRNX

MRNY

<p>Goldman Sachs analyst Salveen Richter reiterated a Hold rating on Moderna with a $49 price target, citing long-term pipeline potential balanced against near-term execution risks. While Moderna's Science Day highlighted promising oncology and autoimmune programs, key readouts are delayed until 2027. The primary near-term catalyst is Phase 3 data for the Merck-partnered therapy intismeran. Citi also maintained a Hold rating with a lower $41 target.</p>

Tip Ranks

Moderna

Merck

Defiance Daily Target 2X Long MRNA ETF

YieldMax MRNA Option Income Strategy ETF

Goldman Sachs

Regeneron Pharma

Agios Pharmac

Citigroup

GS Hldg R

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Hold Rating Reiterated on Moderna as Analyst Keeps $49 Price Target Amid Long-Term Pipeline Potential and Near-Term Execution Risks